- Home
- ABBV vs NVO Comparison
ABBV vs NVO Comparison
Compare ABBV & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABBV | NVO |
|---|---|---|
| Founded | 2012 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.5B | 199.4B |
| IPO Year | 2012 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ABBV | NVO |
|---|---|---|
| Price | $257.32 | $43.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 11 |
| Target Price | ★ $253.71 | $51.00 |
| AVG Volume (30 Days) | 2.8M | ★ 9.4M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.39% | 3.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $61,160,000,000.00 | N/A |
| Revenue This Year | $11.87 | N/A |
| Revenue Next Year | $8.12 | $3.70 |
| P/E Ratio | $103.71 | ★ $13.60 |
| Revenue Growth | ★ 8.57 | N/A |
| 52 Week Low | $190.75 | $35.12 |
| 52 Week High | $267.47 | $64.16 |
Technical Indicators
Market Signals| Indicator | ABBV | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 39.58 |
| Support Level | $242.14 | $43.29 |
| Resistance Level | $261.30 | $51.38 |
| Average True Range (ATR) | 5.03 | 0.90 |
| MACD | -1.39 | -0.16 |
| Stochastic Oscillator | 34.54 | 0.00 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.